The G-protein-coupled receptors LGR4, LGR5 and LGR6 are Wnt signaling mediators, but their functions in squamous cell carcinoma (SCC) are unclear. Using lineage tracing in Lgr5-EGFP-CreERT2/Rosa26-Tomato and Lgr6-EGFP-CreERT2/Rosa26-Tomato reporter mice, we demonstrate that Lgr6, but not Lgr5, acts as an epithelial stem cell marker in SCCs in vivo. We identify, by single-molecule in situ hybridization and cell sorting, rare cells positive for Lgr6 expression in immortalized keratinocytes and show that their frequency increases in advanced SCCs. Lgr6 expression is enriched in cells with stem cell characteristics, and Lgr6 downregulation in vivo causes increased epidermal proliferation with expanded lineage tracing from epidermal stem cells positive for Lgr6 expression. Surprisingly, mice with germline knockout of Lgr6 are predisposed to SCC development, through a mechanism that includes compensatory upregulation of Lgr5. These data provide a model for human patients with germline lossof-function mutations in Wnt pathway genes, including RSPO1 or LGR4, who show increased susceptibility to squamous tumor development.
The mouse skin hair follicle comprises several distinct stem cell populations [1] [2] [3] . Expression of Lrig1 (refs. 3,4) defines a cell population in the hair follicle junctional zone that serves to maintain the hair follicle infundibulum [5] [6] [7] , while quiescent stem cells with Krt15 expression (Krt15 + ) the bulge region act as a reserve stem cell pool that becomes activated in response to stress 8 . Lgr4, Lgr5 and Lgr6 are expressed in stem cells in many tissues, including the small intestine 9 , breast 10 , ovary 11, 12 and hematopoietic system 13 . In the skin, Lgr5 has been genetically linked to a network of genes that are expressed specifically in the hair follicle 14, 15 , while Lgr6 is expressed in the isthmus region, sebaceous gland and interfollicular epidermis 16, 17 .
The LGR receptors bind R-spondins (RSPO) to enhance Wnt/βcatenin signaling [18] [19] [20] [21] . Wnt signaling is known to be activated in the hair germ and hair follicle bulge during the transition from telogen to anagen phase and is critical for the formation of new follicles [22] [23] [24] [25] . However, several reports have also indicated a negative role for Lgr5 in Wnt signaling, including in human colorectal cancers 26, 27 . Moreover, loss-of-function mutations in human RSPO1 (ref. 28 ) and LGR4 (ref. 29 ) increase susceptibility to skin squamous carcinoma development and
LGR6 has been implicated both as a potential tumor-suppressor gene 20 and a breast cancer germline susceptibility gene 30 . Thus, the exact roles of LGR receptors in Wnt signaling and tumorigenesis appear to vary depending on the specific LGR and RSPO family members that are expressed and interact in a given cellular context 27 .
The relationships between normal tissue stem cells and 'cancer stem cells' (CSCs; also known as 'tumor-initiating cells') are controversial and unresolved [31] [32] [33] [34] [35] . Lgr5 has been reported to be a marker of both normal stem cells and CSCs in intestinal adenoma 36 and in gastric cancer 37 , but it remains unclear whether members of this gene family are expressed and, in particular, have a functional role in CSCs in other tumor types including cutaneous SCC.
Here we identify a specific role for Lgr6 as a cutaneous CSC marker. Expression of Lgr6, but not Lgr5, increases during tumor progression and metastasis, while lineage tracing in established tumors shows that only the progeny of Lgr6 + cells form distinct epithelial colonies within SCCs. Nevertheless, germline deletion of Lgr6 predisposes mice to development of SCCs. These data underline the parallels between this mouse model and human patients with germline loss of genes in this pathway, including RSPO1 and LGR4, who also have an increased propensity for SCC development.
RESULTS

Lgr6 is a stem cell marker in squamous carcinoma
Mouse skin SCCs can be initiated with a single dose of dimethylbenzanthracene (DMBA) and promoted by repeated treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) 38 . Tumors from this model have common activating mutations in Ras oncogenes and progress through benign and malignant stages, ultimately metastasizing to cause death 39 . Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma While the existence of stem cells within tumors in this model has been documented 40 , the relationship between these CSCs and markers of normal stem cells is unknown. We first analyzed published gene expression data from samples of normal skin, papillomas, primary carcinomas and matched metastatic tumors from an interspecific FVBBX backcross population 39 . While Lgr6 expression continued to increase during progression, Lgr5 expression showed a decrease, suggesting that Lgr5 may not be required for tumor maintenance (Fig. 1a) .
We investigated the localized expression of Lgr5 and Lgr6 in SCCs from mice carrying an EGFP reporter gene under the control of the Lgr5 or Lgr6 promoter (Lgr5-EGFP-CreERT2 and Lgr6-EGFP-CreERT2 mice 15, 16 ). Staining of tumors using antibodies against GFP (expression from the Lgr5 or Lgr6 promoter; green) or keratin 14 (KRT14; red) ( Fig. 1b-e and Supplementary Fig. 1 ) showed that Lgr6 (Fig. 1e) but not Lgr5 (Fig. 1c) was expressed in distinct colonies of cells distributed throughout the SCCs. Patterns of co-staining for GFP and KRT14 suggest that, while the vast majority of Lgr6 + cells are in the epithelial compartment, the average expression levels of KRT14 in these cells are relatively low as compared to those in adjacent, more differentiated cells ( Supplementary Fig. 1i , inset). These data are thus compatible with the hypothesis that Lgr6 may act as a stem cell marker in squamous carcinomas, whereas Lgr5 does not.
Lgr5 + cells have been reported to be capable of acting as the cells of origin of intestinal and gastric adenomas [41] [42] [43] , cutaneous basal cell carcinomas (BCCs) 44 and SCCs 45 . Schepers et al. 36 exploited the Lgr5-EGFP-CreERT2 +/− targeted knock-in mouse to activate Wnt signaling in Lgr5 + crypt stem cells and showed that the resulting adenomas continued to express Lgr5. We asked whether induction of Ras gene mutations within Lgr5 + stem cells in the hair follicle gives rise to SCCs that continue to express Lgr5 or if it is dispensable for tumor maintenance. We crossed Lgr5-EGFP-CreERT2 +/− or Lgr6-EGFP-CreERT2 +/− mice with Kras LSL-G12D mice carrying a floxed (loxP-flanked) mutant Kras allele 46 . Activation of oncogenic Kras with topical 4-hydroxytamoxifen (4OHT) in Lgr5 + stem cells resulted in some limited sebaceous gland hyperplasia ( Supplementary Fig. 2a ), but, when the mice were further challenged with a back wound stimulus, papillomas readily arose within 4 weeks ( Supplementary Fig. 2b) .
Similar observations were made after activation of Kras in the Lgr6 + stem cell population (data not shown). These results are in agreement with the observations of Lapouge et al. 47 but contrast with the findings of another study 48 , possibly owing to differences in the genetic background of the mice used in the different laboratories.
Surgical removal of papillomas in Lgr5-EGFP-CreERT2 +/− /Kras LSL-G12D/+ mice led to progression to aggressive spindle carcinomas ( Supplementary Fig. 2c ). Lgr5 expression could be detected in the outer root sheath (ORS) of hair follicles in normal skin from Lgr5-EGFP-CreERT2 +/− /Kras LSL-G12D/+ mice (Supplementary Fig. 2d ) and in hair follicles close to the carcinomas, but not in the epithelial carcinoma cells (Supplementary Fig. 2e ). TaqMan and immunofluorescence analyses of three cell lines independently derived from these spindle carcinomas showed an absence of Lgr5 expression ( Supplementary Fig. 2f,g) , while Lgr4 and Lgr6 expression could readily be detected ( Supplementary  Fig. 2f ). We conclude that even tumors arising from Lgr5 + cells in the hair follicle fail to express Lgr5 during tumor progression and that Lgr5 is not a positive driver of SCC growth.
Lineage tracing of Lgr6 + stem cells in squamous tumors
CSCs can give rise to progeny within tumors that continue to fuel cancer development and progression 40, 49 . We carried out lineage tracing within chemically induced skin tumors from Lgr6-EGFP-CreERT2 or Lgr5-EGFP-CreERT2 mice crossed with Rosa26-LSL-Tomato reporter mice 15, 16 (hereafter Lgr6 and Lgr5 reporter mice, respectively). Earlystage papillomas were induced in both double-transgenic lines by standard DMBA treatment followed by 8 weeks of tumor promotion using TPA (Supplementary Fig. 3 A r t i c l e s with tamoxifen and papillomas were collected at different times thereafter (2 d, 3 weeks and 6 weeks), to measure the extent of lineage tracing from either Lgr5 + (Fig. 2a,c ,e,g) or Lgr6 + (Fig. 2b,d ,f,g) stem cells. Imaging of fluorescent cell populations from papillomas 2 d after tamoxifen treatment identified rare GFP and Tomato double-positive cells in the epithelial compartment in Lgr6 reporter mice but not in Lgr5 reporter mice ( Fig. 2a,b ). The number of Tomato + traced cells increased at 3 weeks and 6 weeks, with these cells giving rise to distinct clones that showed evidence of migration from the initial Lgr6 + cells ( Fig. 2d,f) . Some Tomato + traced cells in Lgr6 reporter mice were also observed in the dermis/stromal compartment ( Supplementary Fig.  4b,d ), but these were only a minor population, the significance of which is unknown. In contrast, papillomas from Lgr5 reporter mice displayed very few Tomato + traced cells, even after 6 weeks, and the majority of these were found in the dermal compartment ( Fig. 2e,g and Supplementary Fig. 4a,c) .
We also carried out lineage tracing from Lgr6 + cells in primary carcinomas that arose from 24-30 weeks after tumor initiation. At 2 d ( Fig. 3a,b ), 2 weeks ( Fig. 3c,d ) and 4 weeks ( Fig. 3e,f ) after tamoxifen treatment, there was a significant increase in Tomato + cell numbers in comparison to papillomas. Lgr6-traced Tomato + clones grew rapidly and occupied a major proportion of the carcinoma 4 weeks after Cremediated activation (Fig. 4e,f) . Again, no significant level of traced progeny cells was seen in the equivalent study of Lgr5 reporter mice ( Supplementary Fig. 5a-d) . Interestingly, Driessens et al. 40 demonstrated that clonal populations arising in skin tumors from Krt14-CreER/RosaYFP mice treated with tamoxifen showed a strong decrease in clone numbers over several weeks, but no such decrease was seen in clone number in our studies of serial biopsies of carcinomas from Lgr6-CreER/RosaRFP mice ( Fig. 3) . This suggests that Krt14 initially labels many transit-amplifying cells with poor self-renewal capacity, whereas the Lgr6 + population is already enriched in stem cells that are capable of long-term self-renewal.
The transcription factor SOX2 is expressed in papillomas and squamous carcinomas and was reported to mark a stem cell population that is enriched in tumor-initiating cells 50 . We investigated possible overlap between Sox2 + cells and Lgr6 + cells in SCCs from the DMBA and TPA model by staining for SOX2 in tumors from Lgr6-EGFP-CreERT2 mice. The data in Supplementary Figure 6 show that SOX2 is more widely expressed in a larger population of cells than Lgr6 is, with minimal overlap between the cells expressing these two distinct markers.
Single-cell analysis of Lgr5 and Lgr6 coexpression in normal keratinocytes and tumor cell lines
Analysis of gene expression at the single-cell level is important in the context of CSCs, of which only a small and variable number may be present in solid tumors or tumor cell lines. We carried out gene expression microarray analysis of Lgr4, Lgr5 and Lgr6 levels in mouse cell lines representing various stages of chemically induced tumors 51, 52 . Lgr5 was not expressed above background levels in any of these cell lines, while Lgr4 and Lgr6 were expressed at varying levels ( Supplementary Fig. 7 ). TaqMan analysis ( Fig. 4a) confirmed that Lgr5 was not expressed above the limits of detection except in positive-control back skin samples.
To address the possibility that Lgr5 may be expressed in rare single cells in keratinocyte cultures, we performed Lgr4, Lgr5 and Lgr6 multiplex in situ hybridization 53 . We also analyzed a BCC cell line (Asz001) 54 , as Lgr5 has been reported to be expressed in BCC cells. Expression of Lgr5 was detected in the BCC cells by TaqMan and qPCR analyses, albeit at very low levels ( Fig. 4b, arrow) . In situ hybridization analysis showed that, while Lgr4 was broadly expressed in Asz001 cells, Lgr5 and Lgr6 were more restricted in expression. Interestingly, all three family members were coexpressed in rare single cells ( Fig. 4c and insets) at a frequency of about 0.75% (4 in 533 cells). This observation raises the intriguing possibility that these rare Lgr4, Lgr5 and Lgr6 triple-positive cells are CSCs in the BCC cell line, although further work would be needed to test this hypothesis.
In contrast to the BCC cell line, none of the SCC and keratinocyte cell lines showed substantial Lgr5 expression ( Fig. 4d,e and Supplementary Fig. 8 ). The SCC and keratinocyte cell lines showed different patterns of Lgr6 expression depending on the degree of malignant transformation. In immortalized keratinocytes (C5N cells; Fig. 4d ) and NK cells ( Supplementary Fig. 8 ), Lgr6 was expressed in single cells, together with Lgr4. A much larger population of cells expressed Lgr4 but not Lgr6, as also seen in all of the other cell lines tested ( Fig. 4 and Supplementary Fig. 8 ). Cell lines derived from tumors at more advanced stages (E4 cells, derived from a squamous lung metastasis; Fig. 4e ) showed a high proportion of Lgr6 + cells, in agreement with the observation of high expression levels in these cells by microarray analysis (Supplementary Fig. 7) . These data therefore demonstrate that, at the single-cell level, there appears to be a hierarchy in expression patterns of the LGR gene family. BCCs have distinct Lgr5 + cells, some of which are triplepositive cells that express all three family members. Immortalized keratinocytes lack Lgr5 expression but have rare Lgr6 and Lgr4 double-positive cells, and these appear to increase in number in more advanced tumors.
Multiplex analysis of LGR family gene expression using PCRactivated cell sorting
To determine the levels of coexpression of Lgr4, Lgr5 and Lgr6 at a more quantitative level, we used a novel PCR-activated cell sorting (PACS) technology [55] [56] [57] (Online Methods) . With this method, we were able to identify and sort single cells by performing single-cell TaqMan RT-PCR reactions in >100,000 cells targeting Lgr4, Lgr5 and Lgr6 mRNA sequences. We validated this approach using a subset of the cell lines that were analyzed for LGR gene expression by in situ hybridization and microarrays. Figure 4f shows that almost 100% of the single NK (immortalized keratinocyte), E4 (metastatic squamous carcinoma cell) and ASZ001 (BCC) cells expressed Lgr4, in agreement with the results of in situ hybridization. In contrast, about 1% of the BCC cells expressed Lgr5; however, there was no significant expression in NK cells ( Fig. 4f) . Interestingly, this extremely sensitive approach also identified a small population of E4 cells (around 0.4%) that expressed some Lgr5 (Fig. 4f) , despite the fact that expression analysis by TaqMan ( Fig. 4a) , microarray ( Supplementary Fig. 7 ) or in situ hybridization ( Fig. 4e ) of the whole cell population did not detect any significant Lgr5 transcripts. Lgr6 was expressed in over 90% of the E4 cells and in about 10% of BCC cells, but only in about 1-2% of the NK cells, again in line with the in situ data (Supplementary Fig. 8 ). We also analyzed expression of the same genes in keratinocytes from normal mouse skin. Lgr4 was quite widely expressed (20-30% of keratinocytes), in agreement with previous data on expression in mouse and human skin 16, 58 , while Lgr6, known to be expressed in the upper isthmus as well as the interfollicular epidermis 16 , was found in around 18% and Lgr5 was found in around 2% of single keratinocytes (Fig. 4f) .
Further analysis of these data (Fig. 4g) confirmed the presence of Lgr4, Lgr5 and Lgr6 triple-positive cells in vivo in normal keratinocytes. Around 1.5-2% of normal dorsal telogen skin keratinocytes expressed Lgr5 (Fig. 4f) , and of these about 20% (0.3% of the total population) were triple positive ( Fig. 4g) . Comparable results were seen for the BCC cell line, where of the 1% of the total cell population that expressed Lgr5 (Fig. 4f ) about 18% (0.18% of the total) were triple positive for expression of all three genes (Fig. 4g) . The concordance between the in situ hybridization and PACS sorting data for the cell lines indicates that in vivo there are specific subpopulations of Lgr5 + cells that also coexpress the other family members. Whether these coexpression patterns are involved in cell fate decisions in normal skin homeostasis in vivo remains to be addressed. Interestingly, PACS analysis of primary squamous carcinoma also identified the presence of a small population of triple-positive cells ( Supplementary Fig. 8d,e ). These cells, however, do not appear to be clonogenic in tumors, as the lineage-tracing studies using the Lgr5-EGFP-CreERT2 allele failed to identify a major population of traced epithelial tumor cells.
Lgr6 is enriched in keratinocyte cells with stem cell properties
To test the possibility that Lgr6 + cells represent a stem cell subpopulation, we used the Aldefluor assay [59] [60] [61] [62] to isolate Aldefluor + and Aldefluor − subpopulations from C5N and D3 cultures. Lgr6 expression was elevated in the Aldefluor + fraction in comparison to the Aldefluor − fraction (Fig. 5a,b) , and Aldefluor + cells sorted from C5N cultures were capable of forming more and larger colonies in vitro than Aldefluor − cells (Fig. 5c ). We conclude that Lgr6, and A r t i c l e s not Lgr5, acts as a marker of a stem-like cell population in squamous epidermal cells.
Lgr6 suppresses epidermal cell growth in vitro and in vivo
We next overexpressed Lgr6 in immortalized keratinocytes (NK cells), which have low endogenous levels of Lgr6 mRNA ( Supplementary  Figs. 7 and 8) . Transfection of NK cells with an inducible Lgr6 expression construct (Fig. 5d ) led to growth retardation after addition of doxycycline (Fig. 5e) . To validate this growth-suppressive effect of Lgr6 in epidermal cells, we knocked down Lgr6 in an SCC cell line (E4), which expresses relatively high endogenous levels of Lgr6 ( Fig. 4e  and Supplementary Fig. 7) . We transduced E4 cells with an inducible Lgr6 shRNA construct, which, upon doxycycline administration, elicits efficient knockdown of Lgr6 without altering the levels of either Lgr4 or Lgr5 (Fig. 5f) . Consistent with a growth-suppressive role for Lgr6 in epidermal cells, doxycycline treatment of transduced E4 cells led to increased growth but had no effect on unmodified E4 cells (Fig. 5g) .
Lgr6 knockdown in vivo expands lineage tracing in the skin
Lgr6 is a marker of infundibulum stem cells, but a possible functional role in control of homeostasis in vivo has not been investigated.
Although the Lgr6 −/− mouse is viable 63 , developmental adaptation to loss of expression could lead to compensatory mechanisms for controlling skin homeostasis in the adult mouse. We therefore generated Lgr6knockdown mice, which possess an Lgr6 shRNA construct knocked into the Rosa26 locus that can be induced by addition of doxycycline a b ( Fig. 6a) . Adult Lgr6-knockdown mice were given doxycycline-containing water for 10 d, leading to an approximately 60% reduction in Lgr6 expression levels in the back skin, while Lgr4 and Lgr5 levels were not significantly affected (Fig. 6b) . Immunofluorescence analysis showed that doxycycline administration for this period resulted in an increase in proliferation in the epidermis of Lgr6-knockdown mice, as shown by 5-bromo-2′-deoxyuridine (BrdU) labeling (Fig. 6c) . These results therefore agree with the in vitro data shown in Figure 5g .
We also tested the effect of Lgr6 downregulation in vivo on patterns of lineage tracing from Lgr6 + stem cells. We generated Lgr6 KD +/− /Lgr6-EGFP-CreERT2 +/ /R26RLacZ +/− triple-transgenic mice and administered doxycycline to 8-week-old triple-transgenic animals and controls for 10 d, followed by activation of Cre recombinase by topical 4OHT treatment. Skin samples were collected 7 d thereafter, and 5-bromo-4-chloro-3-indolyl β-d-galactopyranoside (X-gal) analysis showed a striking increase in the number of lacZ + cells in the epidermis (Fig. 6d-f ) in doxycycline-treated mice. This expanded epidermal lineage tracing was accompanied by an increase in clone size ( Fig. 6g ), suggesting that Lgr6 downregulation led to increased proliferation within the Lgr6 progeny compartment in the epidermis, in line with our observations above (Fig. 6c) . It is not possible at this stage to determine whether the increase in traced cells in the epidermis is due to migration from the Lgr6 + cells in the isthmus region or to independent proliferation of the Lgr6 + cells that have been identified within the epidermis 17 . Interestingly, we also saw evidence for Lgr6 lineage tracing within the dermis, which was particularly elevated in the doxycycline-treated animals (Fig. 6d,  bottom) and has not previously been reported. Control skin from non-4OHT-treated adult Lgr6-EGFP-CreERT2 +/− / R26RLacZ +/− mice showed no staining in either the hair follicle or IFE, indicating the non-leakiness of the Lgr6-EGFP-CreERT2 +/− promoter construct (Supplementary Fig. 9 ).
Lgr6 activates Wnt signaling but is a germline tumor-suppressor gene
Lgr5 has been reported to be overexpressed in hepatocellular 64 , colon and ovarian cancers 65 and has also been demonstrated to promote the tumorigenicity of BCC cells 66 . Paradoxically, however, Lgr5 has also been shown to reduce the growth of colorectal cancer cells 26, 27 , and tumor-suppressive roles have been suggested for Lgr4 (ref. 29) and Lgr6 (ref. 20) . Germline loss of RSPO1, the upstream ligand for the LGR family of receptors, or of LGR4 also causes predisposition to the development of squamous carcinoma in humans 28, 29 . We therefore investigated the potential role of Lgr6 as an inducer of Wnt signaling in squamous cells and as a germline tumorsuppressor gene.
We assessed the effects of Lgr6 deregulation on Wnt signaling in keratinocyte cell lines using the well-characterized TOPFlash assay 67 . Overexpression of Lgr6 in multiple epidermal cell lines consistently led to activation of this pathway (Fig. 6h) . Finally, analysis of gene expression data for human head and neck SCCs from The Cancer Genome Atlas (TCGA) (Supplementary Tables 1 and 2) showed a strong connection to the Wnt pathway only for LGR6 and not to any significant extent with LGR5 or LGR4. This supports the notion that
LGR6 is linked to Wnt signaling and may have a unique role in tumors of squamous origin.
To assess the effect of germline inactivation of Lgr6 on tumor susceptibility, we bred Lgr6 −/− mice through multiple generations onto a pure FVB/N genetic background and exposed them to the DMBA/TPA chemical carcinogenesis protocol. The knockout mice showed a highly significant increase in susceptibility to A r t i c l e s papilloma development (Fig. 6i) , as well as shortened carcinoma-free survival (Fig. 6j) . We conclude that Lgr6, in spite of its activity as a positive stimulator of Wnt signaling, acts as a germline suppressor of SCC development, thus mimicking the functions of human Wnt activators RSPO1 and LGR4 as SCC-suppressor genes. One possible explanation for these apparently contradictory results is that 68 . To investigate possible mechanisms of compensation, we derived a series of cell lines from Lgr6 −/− skin SCCs and analyzed expression levels of the other LGR family members. The wild-type mouse carcinomas showed variable activation of the Wnt pathway, as demonstrated by differences in levels of phosphorylated β-catenin 69 . Of the three carcinomas tested, the highest Wnt activity was seen in the cell line (168 cells) that also had the highest level of Lgr6 expression ( Fig. 6k, left) . Variable levels of Wnt activity were also seen in the carcinomas from Lgr6-knockout mice (Fig. 6k, right, and Supplementary Fig. 10 ), but in three of four cases with high activity the level of Lgr5 expression was strongly upregulated. This is particularly noteworthy as all of our expression data show that, in SCCs from wild-type mice, Lgr5 is switched off even at the single-cell level and has no major role as an epithelial cancer stem cell marker. These data therefore identify a mechanism by which cancer stem cells in Lgr6 −/− mice can be regenerated through a feedback mechanism resulting in upregulation of Lgr5.
DISCUSSION
Using a combination of gene expression analysis, lineage tracing, single-molecule in situ hybridization and PACS analysis of single tumor cells, we have shown that Lgr6 satisfies many of the criteria of an SCC stem cell marker. Lineage tracing identified a subpopulation of Lgr6 + tumor cells that give rise to progressively growing epithelial clones.
Lgr6 was enriched in Aldefluor + cells with stem cell properties, and its inhibition resulted in increased proliferation and lineage tracing in the epidermis. Although Lgr5 was not significantly associated with squamous tumor development or progression, it was expressed in rare single cells in a BCC cell line 66 , some of which were triple positive for all three LGR family members. The detection of these triple-positive cells in vivo in basal keratinocyte cells, as well as in primary carcinomas, suggests that they may have a distinct role in stem cell homeostasis, but this question will require further investigation. The model that we believe best explains our results is shown in Supplementary Figure 11 . In this model, an early stem cell population may express Lgr5 and Lgr6 as well as Lgr4, with the initial cell fate choice being determined by competitive interactions of these GPCRs with their R-spondin ligands and other potential effector molecules such as Rnf43 (ref. 70) and Znrf3 (ref. 71 ). Lgr5 expression is maintained in some cells that can give rise to BCCs but lost in cells that commit to the epidermal cell fate. In this stem cell compartment, Lgr6 functions as a brake toward further epidermal commitment and differentiation, such that loss of Lgr6 leads to increased epidermal lineage differentiation and proliferation. It is possible that loss of Lgr6 expression (but continued expression of Lgr4) may be linked to commitment to a more differentiated keratinocyte state. Indeed, the highest levels of Lgr4 expression are seen in cell lines with the most 'epithelial' characteristics such as the immortalized keratinocytes C5N and NK or the differentiated papilloma cell lines MscP1 and Mscp5 (Supplementary Fig. 7) .
Germline deletion of Lgr6 in the mouse caused predisposition to SCC development, as also seen in humans with germline loss of LGR4 (ref. 29) or RSPO1 (ref. 28) . Tumors that arose in Lgr6 −/− mice in fact showed upregulation of Lgr5, particularly in those tumors with the highest levels of Wnt signaling. These data highlight the plasticity and complex control of Wnt/β-catenin signaling in the skin, where activation of the pathway can maintain hair follicle [72] [73] [74] and epidermal 75 stem cell growth, but impairment in hair follicle stem cells stimulates commitment to the epidermal lineage 73, [76] [77] [78] . Elevated expression of β-catenin is negatively associated with normal epidermal proliferation, but its localization in the nucleus is positively associated with growth of Hras-transformed cells 79 . Successful targeting of the Wnt pathway for SCC therapy will require resolution of the complex mechanisms that distinguish signaling in these different biological contexts.
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this was cloned into the doxycycline-inducible F1HtUTG lentiviral vector 81 . For MTT assays, 2,000 (Lgr6 ox and null NK) or 4,000 (Lgr6 shRNA and null E4) cells were seeded in each well of a 96-well plate and the culture medium was replaced every third day. The Vybrant MTT Cell Proliferation Assay (Life Technologies) was performed according to the manufacturer's protocol at the indicated time points after initial seeding. For TOPFlash assays, cells grown in six-well plates were first transfected with 2 µg of the M50 Super 8× TOPFlash plasmid and 0.1 µg of the pRL-TK Renilla luciferase plasmid per well, using Lipofectamine 2000 (Invitrogen). After 6 h, the medium was replaced and doxycycline was added, where appropriate. Two days later, luciferase activity was determined for each well using the Dual-Luciferase Reporter Assay System (Promega) with the GloMax Luminometer, according to the manufacturer's instructions. Figure 7 were described previously (refs. 55,51,82,83 and references therein). NK cells and C5 cells are immortalized keratinocytes derived from wild-type (C5) and Trp53-null (NK) mice. Hras-null cells were derived from a carcinoma induced by DMBA and TPA in Hras-knockout mice 57 . All of the other lines carry initiating mutations in the Hras gene. Cells were grown in serumsupplemented medium in the log phase. RNA extraction with TRIzol reagent was performed followed by purification by Qiagen kit. Gene expression analysis of RNA samples from these lines was carried out using Affymetrix M430 2.0 arrays. Microarray CEL files were background corrected, normalized with RMA using oligo in R and log 2 transformed before analysis. Cell lines were routinely tested for mycoplasma contamination.
Cell lines and microarray analysis. The cell lines shown in Supplementary
Aldefluor, colony formation assays and qPCR. Cells cultured in vitro were trypsinized and stained with Aldefluor (and DEAB) (Stemcell Technologies), according to the manufacturer's instructions. The cells were then sorted into Aldefluor + and Aldefluor − fractions on the BD FACSAria III. For expression analyses, RNA was extracted from the sorted cells using TRIzol (Invitrogen), and reverse transcription was performed using the High-Capacity Reverse Transcription kit (Life Technologies). qPCR reactions were subsequently run on the AB7900HT, using TaqMan gene expression assays for Lgr4 (Mm00554385_m1), Lgr5 (Mm00438890_m1 and Mm01251804_m1) and Lgr6 (Mm01291336_m1) (Life Technologies). Within each sample, the Ct value for Actb was used as a reference to calculate ∆Ct values for genes of interest. For each qPCR experiment, all samples were run in technical triplicates and the mean ∆Ct value among the technical triplicates was determined for genes of interest; all samples were further run in biological triplicates and the data presented show the mean and s.e.m. among these biological triplicates.
For colony-formation assays, 2,000 cells were seeded in each well of a sixwell plate and grown in a 37 °C cell culture incubator for 19 d. The cells were then fixed in ice-cold methanol for 10 min and finally stained with crystal violet for 10 min.
Statistical analysis.
Statistical analyses were carried out using the Prism software package (GraphPad). The significance of differences between two groups was determined using the unpaired, two-tailed Student's t test: *P < 0.05; **P < 0.01; ***P < 0.001. F tests indicated no evidence of a statistically significant difference in the variances of all groups being compared, except in Figures 5d,g (null samples) and 6c,e,h (H11 samples) , where Welch's correction was applied. Significance analysis for multiple groups was performed with ANOVA.
As we could not anticipate an effect size before performing our initial experiments, rather than performing a power calculation we defined cohort size by estimating from prior work. We evaluated our prior experimental evidence from unrelated experiments to define a size that allowed us to detect both statistically as well as practically a meaningful difference between the genotypes. In our experiments using the two-stage carcinogenesis protocol, the sample size was generally between 10 and 20 mice, assuming a less than 5% dropout rate during carcinogenesis.
Data availability. The cell line gene expression microarray data have been deposited in the Gene Expression Omnibus (GEO) with accession GSE88742.
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